Literature DB >> 26752112

Variable Intra-Tumor Genomic Heterogeneity of Multiple Lesions in Patients With Hepatocellular Carcinoma.

Ruidong Xue1, Ruoyan Li1, Hua Guo2, Lin Guo2, Zhe Su1, Xiaohui Ni3, Lisha Qi4, Ti Zhang4, Qiang Li4, Zemin Zhang1, Xiaoliang Sunney Xie3, Fan Bai5, Ning Zhang6.   

Abstract

BACKGROUND & AIMS: Many patients with hepatocellular carcinoma (HCC) have multiple lesions (primary tumors, intrahepatic metastases, multiple occurrences, satellite nodules, and tumor thrombi); these have been associated with a poor prognosis and tumor recurrence after surgery. We investigated the clonal relationship among these lesions on the basis of genetic features.
METHODS: We collected 43 lesions and 10 matched control samples (blood or nontumorous liver) from 10 patients with hepatitis B virus-associated HCC treated at Tianjin Cancer Hospital (China) from January 2013 through May 2014. We performed exome and low-depth, whole-genome sequencing on these samples. Genomic aberrations, including somatic mutations and copy number variations, were identified using germline DNA as control. We compared the genetic features of different lesions from each patient and constructed phylogenetic trees to depict their evolutionary histories.
RESULTS: In each patient, mutations shared by all the lesions were called ubiquitous mutations. The percentage of ubiquitous mutations varied from 8% to 97% among patients, indicating variation in the extent of intratumor heterogeneity. Branched evolution was evident, with somatic mutations, hepatitis B virus integrations, and copy number variations identified on both the trunks and branches of the phylogenetic trees. Intrahepatic metastases and tumor thrombi contained some, but not all, of the mutations detected in their matched primary lesions. By contrast, satellite nodules shared approximately 90% of mutations detected in primary lesions. In a patient with multicentric tumors, 6 lesions were assigned to 2 distinct groups, based on significant differences in genetic features. In another patient with combined hepatocellular and intrahepatic cholangiocarcinoma, the physically separate HCC and cholangiocarcinoma lesions shared 102 mutations.
CONCLUSIONS: The extent of intratumor heterogeneity varies considerably among patients with HCC. Therefore, sequence analysis of a single lesion cannot completely characterize the genomic features of HCC in some patients. Genomic comparisons of multiple lesions associated with HCCs will provide important information on the genetic changes associated with tumor progression.
Copyright © 2016 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Liver Cancer; Metastasis; Pathogenesis; Spread

Mesh:

Substances:

Year:  2016        PMID: 26752112     DOI: 10.1053/j.gastro.2015.12.033

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  82 in total

1.  Genomic and Transcriptomic Profiling of Combined Hepatocellular and Intrahepatic Cholangiocarcinoma Reveals Distinct Molecular Subtypes.

Authors:  Ruidong Xue; Lu Chen; Chong Zhang; Masashi Fujita; Ruoyan Li; Shu-Mei Yan; Choon Kiat Ong; Xiwen Liao; Qiang Gao; Shota Sasagawa; Yanmeng Li; Jincheng Wang; Hua Guo; Qi-Tao Huang; Qian Zhong; Jing Tan; Lisha Qi; Wenchen Gong; Zhixian Hong; Meng Li; Jingmin Zhao; Tao Peng; Yinying Lu; Kiat Hon Tony Lim; Arnoud Boot; Atushi Ono; Kazuaki Chayama; Zemin Zhang; Steve George Rozen; Bin Tean Teh; Xin Wei Wang; Hidewaki Nakagawa; Mu-Sheng Zeng; Fan Bai; Ning Zhang
Journal:  Cancer Cell       Date:  2019-05-23       Impact factor: 31.743

Review 2.  Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy.

Authors:  Renumathy Dhanasekaran; Jean-Charles Nault; Lewis R Roberts; Jessica Zucman-Rossi
Journal:  Gastroenterology       Date:  2018-11-04       Impact factor: 22.682

Review 3.  The Metabolism of Renal Cell Carcinomas and Liver Cancer.

Authors:  Tu Nguyen; Anne Le
Journal:  Adv Exp Med Biol       Date:  2018       Impact factor: 2.622

4.  Single cell profiling reveals window for immunotherapy in liver cancers.

Authors:  Jesper B Andersen
Journal:  Hepatobiliary Surg Nutr       Date:  2018-02       Impact factor: 7.293

5.  Diverse modes of clonal evolution in HBV-related hepatocellular carcinoma revealed by single-cell genome sequencing.

Authors:  Meng Duan; Junfeng Hao; Sijia Cui; Daniel L Worthley; Shu Zhang; Zhichao Wang; Jieyi Shi; Longzi Liu; Xiaoying Wang; Aiwu Ke; Ya Cao; Ruibin Xi; Xiaoming Zhang; Jian Zhou; Jia Fan; Chong Li; Qiang Gao
Journal:  Cell Res       Date:  2018-01-12       Impact factor: 25.617

6.  Dysregulation of the cohesin subunit RAD21 by Hepatitis C virus mediates host-virus interactions.

Authors:  Shira Perez; Michael Gevor; Ateret Davidovich; Antony Kaspi; Katreena Yamin; Tom Domovich; Tomer Meirson; Avi Matityahu; Yehuda Brody; Salomon M Stemmer; Assam El-Osta; Izhak Haviv; Itay Onn; Meital Gal-Tanamy
Journal:  Nucleic Acids Res       Date:  2019-03-18       Impact factor: 16.971

Review 7.  Frequently mutated genes/pathways and genomic instability as prevention targets in liver cancer.

Authors:  Chinthalapally V Rao; Adam S Asch; Hiroshi Y Yamada
Journal:  Carcinogenesis       Date:  2016-11-12       Impact factor: 4.944

Review 8.  Clonal expansion in non-cancer tissues.

Authors:  Nobuyuki Kakiuchi; Seishi Ogawa
Journal:  Nat Rev Cancer       Date:  2021-02-24       Impact factor: 60.716

9.  Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma.

Authors:  Alexander Gerbes; Fabien Zoulim; Herbert Tilg; Jean-François Dufour; Jordi Bruix; Valérie Paradis; Riad Salem; Markus Peck-Radosavljevic; Peter R Galle; Tim F Greten; Jean-Charles Nault; Matias A Avila
Journal:  Gut       Date:  2017-11-17       Impact factor: 23.059

10.  Tumor Cell Biodiversity Drives Microenvironmental Reprogramming in Liver Cancer.

Authors:  Lichun Ma; Maria O Hernandez; Yongmei Zhao; Monika Mehta; Bao Tran; Michael Kelly; Zachary Rae; Jonathan M Hernandez; Jeremy L Davis; Sean P Martin; David E Kleiner; Stephen M Hewitt; Kris Ylaya; Bradford J Wood; Tim F Greten; Xin Wei Wang
Journal:  Cancer Cell       Date:  2019-10-03       Impact factor: 31.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.